<DOC>
	<DOC>NCT00064467</DOC>
	<brief_summary>This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.</brief_summary>
	<brief_title>Lethargic Depression Study</brief_title>
	<detailed_description>A Multicenter, Double-Blind, Placebo-controlled comparison of the efficacy and safety of flexible dose extended-release bupropion (HCl) 300-450 mg/day and placebo administered for eight weeks for the treatment of adult outpatients with major depressive disorder including symptoms of decreased energy, pleasure, and interest</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Lethargy</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Inclusion criteria: Primary diagnosis of MDD with current duration lasting 12 weeks but no greater than 2 years. Generally in good health. Subject must read and write at a level sufficient to provide written informed consent. Exclusion criteria: Current or past history of seizure disorder. Subject has a primary diagnosis or received treatment for panic disorder, obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), acute stress disorder, Bipolar I or II disorder, schizophrenia, or other psychotic disorder. Currently using illicit drugs or other psychotropic drugs. Patient poses a current suicidal risk or has attempted suicide in the past 6 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>lethargic</keyword>
	<keyword>decreased interest</keyword>
	<keyword>decreased motivation</keyword>
	<keyword>depression</keyword>
</DOC>